This clinical-stage biotechnology company develops precision medicines for kidney disease. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. In 2020, Aduro Biotech – founded in 2001 by Triton to explore cancer therapies enabled by Triton’s research – was acquired by Chinook. In a subsequent transaction with Van Herk Investments, a leading European life-sciences investor, Chinook created a new company called Sairopa to pursue non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform.
Chinook’s lead program is atrasentan, a Phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a Phase 1B trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small-molecule LDHA inhibitor for treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases.
Chinook is building its pipeline by leveraging insights in kidney single-cell RNA sequencing, human-derived organoids, and new translational models to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.